Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement with Chinese startup Foreseen Biotechnology for the latter’s lead pipeline candidate, FS001. This agreement grants Ipsen exclusive rights to develop, manufacture, and commercialize the antibody-drug conjugate (ADC) on a global scale.
As per the terms of the deal, Ipsen will be responsible for conducting the Phase I clinical study of the molecule and all subsequent development activities, including IND filing, manufacturing, and global commercialization. Foreseen Biotechnology is set to receive up to USD 1.03 billion, which encompasses upfront payments and milestone payments tied to development, regulatory, and commercial achievements, as well as tiered royalties based on future global sales.
FS001 is a potentially first-in-class ADC that targets a novel tumor-associated antigen overexpressed in many solid tumors, playing a pivotal role in tumor proliferation and metastasis. The drug is designed with an innovative, stable, and cleavable linker that is coupled with a highly potent topoisomerase I inhibitor. FS001 has demonstrated promising preclinical efficacy in models of multiple drug-resistant cancers.- Flcube.com
